CytomX Therapeutics, Inc. (CTMX) Quick Ratio
- Quick ratio · latest quarter: Value 9.23×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 9.23× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $367.77M ÷ $39.86M ≈ 9.23× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 367.77M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 39.86M USD | Liabilities, Current |
| Cash and equivalents | 17.22M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 313.06M USD | Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 37.49M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $367.77M | $39.86M | $17.22M | $313.06M | $37.49M | (m) | 9.23× |
| 2026-03-31 | $347.35M | $34.02M | $28.83M | $317.88M | $646.00K | (m) | 10.21× |
| 2025-12-31 | $139.06M | $46.62M | $12.67M | $124.39M | $2.01M | (m) | 2.98× |
| 2025-09-30 | $145.25M | $41.03M | $34.19M | $109.44M | $1.63M | (m) | 3.54× |
| 2025-06-30 | $159.96M | $39.22M | $49.04M | $109.05M | $1.87M | (m) | 4.08× |
| 2025-03-31 | $81.84M | $50.20M | $47.60M | $32.28M | $1.96M | (m) | 1.63× |
| 2024-12-31 | $103.73M | $85.77M | $38.05M | $62.57M | $3.10M | (m) | 1.21× |
| 2024-09-30 | $120.94M | $119.23M | $40.58M | $77.01M | $3.35M | (m) | 1.01× |
| 2024-06-30 | $139.96M | $142.86M | $43.25M | $93.94M | $2.77M | (m) | 0.98× |
| 2024-03-31 | $163.46M | $144.54M | $36.19M | $114.10M | $13.18M | (m) | 1.13× |
| 2023-12-31 | $177.94M | $155.91M | $17.17M | $157.34M | $3.43M | (m) | 1.14× |
| 2023-09-30 | $196.53M | $146.79M | $26.02M | $168.09M | $2.42M | (m) | 1.34× |
| 2023-06-30 | $182.76M | $141.38M | $57.54M | $123.32M | $1.90M | (m) | 1.29× |
| 2023-03-31 | $205.59M | $151.26M | $56.36M | $148.15M | $1.09M | (m) | 1.36× |
| 2022-12-31 | $229.64M | $152.61M | $193.65M | $0.00 | $35.99M | (m) | 1.50× |
| 2022-09-30 | $196.00M | $97.84M | $95.04M | $99.25M | $1.71M | (m) | 2.00× |
| 2022-06-30 | $229.18M | $99.44M | $129.29M | $98.88M | $1.01M | (m) | 2.30× |
| 2022-03-31 | $263.55M | $102.77M | $163.49M | $99.04M | $1.02M | (m) | 2.56× |
| 2021-12-31 | $306.02M | $106.32M | $205.53M | $99.70M | $790.00K | (m) | 2.88× |
| 2021-09-30 | $237.18M | $99.77M | $236.28M | $5.00K | $887.00K | (m) | 2.38× |
| 2021-06-30 | $267.11M | $93.38M | $256.15M | $10.03M | $931.00K | (m) | 2.86× |
| 2021-03-31 | $394.55M | $98.05M | $329.67M | $64.13M | $756.00K | (m) | 4.02× |
| 2020-12-31 | $316.92M | $100.92M | $191.86M | $124.26M | $798.00K | (m) | 3.14× |
| 2020-09-30 | $321.62M | $102.03M | $176.81M | $144.27M | $543.00K | (m) | 3.15× |
| 2020-06-30 | $346.61M | $98.78M | $291.39M | $55.01M | $206.00K | (m) | 3.51× |
| 2020-03-31 | $377.93M | $106.00M | $143.29M | $104.64M | $130.01M | (m) | 3.57× |
| 2019-12-31 | $296.16M | $85.59M | $188.43M | $107.72M | $13.00K | (m) | 3.46× |
| 2019-09-30 | $325.72M | $76.13M | $164.65M | $161.07M | $7.00K | (m) | 4.28× |
| 2019-06-30 | $359.15M | $78.67M | $149.39M | $199.75M | $10.00M | (m) | 4.57× |
| 2019-03-31 | $396.64M | $96.22M | $190.41M | $206.19M | $44.00K | (m) | 4.12× |
| 2018-12-31 | $436.22M | $97.91M | $247.58M | $188.55M | $97.00K | (m) | 4.46× |
| 2018-09-30 | $464.62M | $86.27M | $259.75M | $204.81M | $56.00K | (m) | 5.39× |
| 2018-06-30 | $360.28M | $83.21M | $132.91M | $202.24M | $25.14M | (m) | 4.33× |
| 2018-03-31 | $361.56M | $69.71M | $142.16M | $219.32M | $81.00K | (m) | 5.19× |
| 2017-12-31 | $384.25M | $61.15M | $177.55M | $196.56M | $10.14M | (m) | 6.28× |
| 2017-09-30 | $371.46M | $71.24M | $284.23M | $47.05M | $40.18M | (m) | 5.21× |
| 2017-06-30 | $336.07M | $60.63M | $272.86M | $63.06M | $158.00K | (m) | 5.54× |
| 2017-03-31 | $162.74M | $37.13M | $85.66M | $76.86M | $213.00K | (m) | 4.38× |
| 2016-12-31 | $184.10M | $35.77M | $104.64M | $77.29M | $2.16M | (m) | 5.15× |
| 2016-09-30 | $178.71M | $23.68M | $59.76M | $118.71M | $240.00K | (m) | 7.55× |
| 2016-06-30 | $196.08M | $22.22M | $62.38M | $133.42M | $285.00K | (m) | 8.82× |
| 2016-03-31 | $180.95M | $17.00M | $67.90M | $112.74M | $316.00K | (m) | 10.64× |
| 2015-12-31 | $187.46M | $15.74M | $59.82M | $126.89M | $744.00K | (m) | 11.91× |
| 2015-09-30 | (m) | $13.97M | $36.19M | (m) | $406.00K | (m) | (m) |
| 2015-06-30 | (m) | (m) | $45.84M | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | $7.82M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $11.16M | $64.40M | (m) | $1.88M | (m) | (m) |
| 2014-09-30 | (m) | (m) | $53.31M | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | $8.70M | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | $14.75M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |